Art

J-GLOBAL ID：202102226149420239   Reference number：21A2819915

Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer

非小細胞肺癌の治療におけるニボルマブとペンブロリズマブの固定用量対体重ベース投与レジメンの予算影響分析【JST・京大機械翻訳】

Author (10)： Monirul Sanjana (Department of Pharmacy, Hopital Avicenne, Hopitaux Universitaires Paris Seine Saint-Denis, 93000 Bobigny, France) ,  Rigal Marthe (Department of Pharmacy, Hopital Avicenne, Hopitaux Universitaires Paris Seine Saint-Denis, 93000 Bobigny, France) ,  Chouahnia Kader (Department of Medical and Thoracic Oncology, Hopitaux Universitaires Paris Seine Saint-Denis, 93000 Bobigny, France) ,  Jouan Melisande Le (OMEDIT Ile-De-France, 75014 Paris, France) ,  Apparuit Maxime (Department of Pharmacy, Hopital Avicenne, Hopitaux Universitaires Paris Seine Saint-Denis, 93000 Bobigny, France) ,  Paix Adrien (Institut de Radiotherapie de Bobigny, rue Lautreamont, 93000 Bobigny, France) ,  Jacolot Anne (Department of Pharmacy, Hopital Avicenne, Hopitaux Universitaires Paris Seine Saint-Denis, 93000 Bobigny, France) ,  Zelek Laurent (Department of Medical and Thoracic Oncology, Hopitaux Universitaires Paris Seine Saint-Denis, 93000 Bobigny, France) ,  Duchemann Boris (Department of Medical and Thoracic Oncology, Hopitaux Universitaires Paris Seine Saint-Denis, 93000 Bobigny, France) ,  Duchemann Boris (Gustave Roussy Cancer Campus, Laboratoire D’immunomonitoring en Oncologie, CNRS-UMS 3655 and INSERM-US23, 94805 Villejuif, France)
Material： Vaccines (Web)
Volume： 8  Issue： 4  Page： 730  Publication year： 2020 
JST Material Number： U7290A  ISSN： 2076-393X  Document type： Article
Article type： 原著論文  Country of issue： Switzerland (CHE)  Language： ENGLISH (EN)

Abstract/Point： In 2018, dosing regimens of th...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=21A2819915&from=J-GLOBAL&jstjournalNo=U7290A") }}

Thesaurus term： insurance ,  French Republic ,  radiation dose ,  drug therapy ,  public health ,  effectiveness ,  economic effect ,  *lung tumor ,  *non-small cell lung cancer ,  *drug administration schedule ,  university hospital
Semi thesaurus term： 治療期間 ,  臨床研究 ,  *ニボルマブ ,  免疫チェックポイント阻害剤 ,  *ペムブロリズマブ , 【Automatic Indexing@JST】

Author keywords (6)： budget impact analysis ,  lung cancer ,  nivolumab ,  pembrolizumab ,  fixed dose ,  cancer immunotherapy

JST classification (2)： Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Reference (35)：

• Fact Sheets by Cancer. Available online: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (accessed on 30 October 2020). Le Cancer du Poumon-Les Cancers les Plus Fréquents. Available online: http://www.e-cancer.fr/Professionnels-de-sante/Les-chiffres-du-cancer-en-France/Epidemiologie-des-cancers/Les-cancers-les-plus-frequents/Cancer-du-poumon (accessed on 30 October 2020). Haute Autorité de Santé-Cancer Broncho-Pulmonaire: Le Parcours de Soins Doit Préserver en Priorité Une Qualité de Vie. Available online: https://www.has-sante.fr/portail/jcms/c_1651595/fr/cancer-broncho-pulmonaire-le-parcours-de-soins-doit-preserver-en-priorite-une-qualite-de-vie (accessed on 30 October 2020).
• Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2002, 346, 92-98.
• Barlesi, F.; Mazieres, J.; Merlio, J.-P.; Debieuvre, D.; Mosser, J.; Lena, H.; Ouafik, L.; Besse, B.; Rouquette, I.; Westeel, V.; et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 2016, 387, 1415-1426.
• Remon, J.; Passiglia, F.; Ahn, M.-J.; Barlesi, F.; Forde, P.M.; Garon, E.B.; Gettinger, S.; Goldberg, S.B.; Herbst, R.S.; Horn, L.; et al. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J. Thorac. Oncol. 2020, 15, 914-947.
• Brahmer, J.; Horn, L.; Hossein, B.; Ramalingam, S.; Pluzanski, A.; Burgio, M.; Garassino, M.; Chow, L.; Gettinger, S.; Crino, L.; et al. O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response. J. Thorac. Oncol. 2019, 14, S1152-S1153.

Terms in the title (9)： 非小細胞肺癌 ,  治療 ,  ニボルマブ ,  ペンブロリズマブ ,  用量 ,  体重 ,  投与レジメン ,  予算 ,  影響分析